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STUDY OF SERUM GAMMA - GLUTAMYL  TRANSFERASE  
LEVELS  IN  FEMALE  PATIENTS  WITH  METABOLIC   
SYNDROME 
INTRODUCTION :  
 
 Metabolic syndrome is a combination of Medical disorders that increase the 
risk of developing Cardiovascular disease and Diabetes1.  It affects a great number 
of people and prevalence increases with age.  Metabolic syndrome is also known 
as syndrome-X, Insulin Resistance syndrome, Raeven’s syndrome, CHAOS 
(Australia) or Metabo (Japan). 
 
 GGT is a Potential biomarker for preclinical development of 
artherosclerosis because GGT was detected in atheromatous plaques of carotid and 
coronary arteries triggering oxidation of LDL. 
Signs and Symptoms2: 
 
1. Fasting Hyper glycemia – Diabetes Mellitus Type II or Impaired Fasting 
Glucose, Impaired Glucose tolerance or Insulin resistance. 
2. High blood pressure 
3. Central obesity (Visceral, Male pattern or Apple shaped Adiposity) Over 
weight with fat deposits mainly around the waist. 
4. Decreased HDL – Cholesterol 
5. Elevated Triglycerides  
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ASSOCIATED FINDINGS : 
 
1. Elevated uric acid levels 
2. Fatty Liver (Especially in concurrent obesity) Progressing to non-
alcoholic liver diseases  
3. Polycystic ovarian syndrome  
4. Haemochromatosis (Iron over load)  
5. Acanthosis Nigricans (skin condition featuring dark patches) 
 
DIAGNOSTIC CRITERIA :  
  
I. The WHO Criteria (1999) : Presence of Diabetes Mellitus / Impaired Glucose   
    Tolerance, Impaired fasting glucose  and any 2 of the following criteria. 
1. Blood pressure > or = 140/90mm of Hg. 
2. Central obesity or Body Mass Index > 30Kg /m2 
3. Dyslipidemia (Triglycerides > or = 1.695 mmol / lit and  
     HDL – C <or = 0.9 mmol / lit for males 
                 <or =1mmol / lit for females      
4.  Micro albumin urea – urinary albumin excretion ratio >or =20mg/mt or 
Albumin creatinine ratio > 30mg /kg/gm 
II. NCEP3 (National Cholesterol Education programme) Adult Treatment  
Panel III. (2001): Any three of the following criteria  
1. Central obesity : waist circumferance  
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   >or = 102cms or 40 inches (Males) 
   >or = 88cms or 36 inches (Females) 
2. Dyslipidaemia : TG >or= 1.695 mmol / l (150mg/dl). 
3. Dyslipidaemia: HDL-C <40 mg/dl (male) 
      < 50mg/dl (females) 
4. Blood Pressure : >or =130/85 mm of Hg 
5. Fasting plasma glucose >or = 6.1 mmol/l (110mg/dl) 
 
III. UPDATED NCEP2 
 
1. Elevated waist Circumference  
   Men   >or = 40 inches (102 cms) 
   Women >or = 35 inches (88 cms) 
2. Elevated Triglycerides >or = 150 mg/dl 
3. Decreased HDL – C < 40 mg / dl in Males 
         < 50mg/dl in females 
4. Elevated Blood pressure >or = 130/85 mm of Hg or use of medication 
for Hypertension. 
5. Elevated fasting Glucose of 100 mg/dl (5.6 mmol /litre) or use of 
medication for Diabetes – Mellitus 
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ETIOLOGY 
 
 The Cause of metabolic syndrome is unknown 
 The Pathophysiology is extremely complex. Most patients are older, obese, 
sedentary and have a degree of insulin resistance. The most important factors in 
order are  
 
(i) Aging 
(ii) Genetics 
(iii) Life-style, i.e, Low physical activity and excess caloric Intake. 
(iv) Some have pointed to oxidative stress due to variety of causes 
including ‘INCREASING URIC ACID LEVELS’4 caused by dietary 
fructose. 
 
However number of markers of systemic  Inflammation including C - 
Reactive protein, Fibrinogen, Th-b, Tumor Necrosis factor Alpha (TNF α) 
are also increased.  
Who is at risk for Metabolic syndrome5? 
(i) A large waist line or abdominal obesity. 
(ii) Lack of physical activity 
(iii) Insulin resistance.  
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 Other groups who are at increased risk of developing metabolic syndrome 
include. 
1. People with a sibling or parent with diabetes 
2. People with personal history of diabetes 
3. People with a personal history of polycystic ovarian syndrome. 
 
RISK for Heart diseases : Having metabolic syndrome increases risk for heart 
diseases. Heart disease risk can be  divided into short term risk (risk for having a 
heart attack or dying of heart disease in the next 10 yrs) and Long term risk (risk 
for developing heart disease over Lifetime). 
 
 According to the June issue of “Human Molecular Genetics” (By Kevin 
Mckeever June 19 2008) at Washington  University School  of Medicine found the 
Variation on the CD-36 Gene located in part of Chromosome – 7, previously 
associated with metabolic syndrome6. 
 
EPIDEMIOLOGY 7: 
 
 About 47 million adults in United States (25%) have metabolic syndrome. 
Metabolic syndrome is common in African American Women than in African 
American men. It is known in Mexican American women than in Mexican 
American men.  Mexican American have the highest rate of metabolic syndrome. 
 6
(31.09%) followed by Caucasians 23.8 percent and African American 21.6 
percent. South Asians have an increased risk for Metabolic syndrome. 
 
 According to American Heart Association 2008 update the age adjusted  
prevalence of metabolic syndrome for adults is 23.7 percent. The prevalence is 42 
percent for age  greater than 70 yrs  and 43.5 percent for age group 60-69 yrs and 
6.7 percent among 20-29 yrs. People reporting other race of Ethnicity prevalence 
is 20.3 percent8. 
 
GGT 
 
 Gamma Glutamyl Transferase is a cell surface protein contributing to extra 
cellular catabolism of glutathione  (GSH)9 The enzyme is produced in many 
tissues, but most GGT in serum in derived  from liver. In the serum GGT is 
primarily carried with lipoprotein and albumin. 
 
 One hypothesis for the relation of GGT levels and Vascular disease hold 
that GGT itself is PROATHERO GENIC10.  GGT has been reported to occur in 
atherosclerotic plaques11, which might support this hypothesis.  The origin of GGT 
in plaques could be through influx of lipoproteins. One of the products of GSH 
hydrolysis produced by GGT is cystenyl – Glycine which can generate super oxide 
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anion radicals through its interaction with free ion. This would promote 
atherogenesis via LDL oxidation 
     
 GGT is present in serum and all cells except muscles21 . In the cell it is 
located in cell membrane and less in cytosol.  Its functions are that it transports 
amino acids and peptides across cell membrane into cells.  It is involved in 
glutathione metabolism. 
 
clinical significance of GGT  : 
 
 Origin of GGT  is primarily from the Hepatobiliary system. So it’s level is 
increased in all forms of liver disease.  
a. Earliest and highest elevation in obstructive jaundice, cholangitis and 
cholecystitis. Increase is 5-30 times the normal levels. 
b. Infectious hepatitis Increase is 2-5 times normal levels. 
c. Early and high elevations in individuals with primary or secondary 
neoplasms. 
d. Increase of 2-5 times normal GGT activity in fatty liver. 
e. Transient increase in  drug intoxications is observed. 
f. Acute and chronic pancreatitis and in carcinoma head of pancreas 
obstructing biliary flow – Increase is  5-15 times of normal activity. 
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g. Increase in levels of serum GGT in alcoholic cirrhosis and heavy 
drinkers. 
h. In myocardial infarction  – GGT is normal. But increase may occur by 
4th hour peak in 4 days. Why? Secondary to liver damage due to cardiac 
insufficiency. 
i. Increase in serum levels of GGT – elevated in drug intake (Phenytoin, 
Phenobarbitone) due to induction of new enzymes activity by 
anticonvulsants. 
j. High levels of GGT are present in prostate (50% higher activity in sex 
of men than women. 
k. At times increased in prostatic malignancy. 
l. Irradiation of tumors. Increase in GGT activity in serum. 
m. Origin of GGT in urine is from kidneys and gut.    
 
Since GGT is Proatherogenic, it is essential to find the levels of Serum 
Gamma Glutamyl Transferase in individuals with Metabolic Syndrome which is 
already associated with (high) cardiac risk factors. 
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OBJECTIVE 
 
 To study the level of GGT in serum of female patients with 
Metabolic Syndrome. 
 
 10
 
MATERIALS AND METHODS 
 
 The dissertation study was carried out in the Hypertensive  Out-Patient 
Department of  Thanjavur Medical College Hospital. 
 
 My study group comprises of 100 females with Metabolic syndrome 
according  to 3/5 criteria of National Cholesterol education programme (NCEP), in 
whom fasting serum levels of Gamma-Glutamyl Transferase levels were 
estimated. 
 
 The patients were identified as having Metabolic syndrome according to the 
following criteria. 
1. Elevated waist circumference of >or= 35 inches (88 cms) 
2. Elevated Triglycerides >or=150 mg/dl 
3. Decreased HDL – C<or=50 mg/dl 
4. Elevated Blood pressure of >or= 130/85 mm of Hg. 
5. Elevated fasting Glucose of >or= 100mg/dl. 
 
   All the people in the study group were enquired by the following  
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Questionnaire  
 1. Name Address 
 2. Age   
 3. Gender  
 4. Diet  
 5. Occupation  
 6. Religion  
 7. Complaints  
 8. Past History suggestive of  
   DM/BA/TB   
  PIH or GDM  
 9. Personal History :   
  H/O Alchohol in take 
Menstrual History 
 
 10. Family History of Obesity,  
HT, DM, BA, TB, Stroke,  
CV diseases. 
 
    
    Treatment History :  What Anti Hypertensive drug is she on? and how 
long? 
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General  Examination 
 
a. Anaemia     Height : 
b. Jaundice     Weight : 
c. Xanthalesma    Body mass index 
d. Cyanosis     Waist circumference  
e. Clubbing      Measurement 
f. Pedaloedema  
g.Lymphadenopathy 
h. Pulse rate 
i. Blood pressure 
 
Systemic Examinations. 
 
1. Cardiovascular System 
2. Respiratory system 
3. Abdomen 
4. Central Nervous system 
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METHODOLOGY 
 
Study Group Humans 
Criteria :- Female  Patients in the age group 30 to 75 yrs.  
Inclusion Criteria   
1. Obesity 
2. Hypertension 
3. Dyslipidemias over 150 mg/dl TAG Blood 
4. Fasting blood sugar More than 106 mg/dl 
5. HDL less than 50mg/dl 
 
Exclusion Criteria 
1. Liver diseases 
2. Renal Diseases 
3. Alcoholism 
4. Drug in take (Anticoagulants) 
5. Males (Prostatic GGT) 
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METHODOLOGY: 
 
 The following parameters were measured by using different methodologies. 
 Parameters included under study supporting diagnosis of Metabolic 
syndrome. 
 
I. Gamma – Glutamyl Transferase  
II. 1. Fasting Blood Glucose 
 2. Serum Cholesterol 
 3. HDL – Cholesterol 
 4. Serum Triglycerides  
 5. LDL  
 6. SG OT 
 7. SG PT 
 8. Alkaline Phosphatase 
 9. Serum Uric acid 
 10. Serum Urea 
 11. Serum Creatinine  
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Estimation of γ – Glutamyl Transferase levels in serum. 
Kinetic (SZASZ Method) 49: 
 
Principle : 
  γ – Glutamyl transpeptidase catalyses the transfer of Gamma-
Glutamyl group from the substrate Gamma-Glutamyl para-Nitroanilide to Glycyll 
Glycine releasing free P-Nitro aniline which absorbs light at 405nm. 
 
  Enzyme activity is proportional to increase in absorbance at 405nm. 
 
  GPNA + Glycyl Glycine   γ – GT     L- γ –Glutanyl Glycyl  
         Glycine + P-Nitro aniline 
  GPNA = L- γ – Glutamyl – P-Nitroanilide. 
 
Reagent contents: 
 
Reagent 1 (substrate) 
 
 Glycyl Glycine     94 mmol/L 
 L- γ -Glutamyl – P-Mitroanilide  3.2 mmol/L 
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Reagent  1A (Buffer) 
 
 Tris Buffer (PH-8.20)    200mmol/L 
 Surfactant      0.2% 
 
Reagent Preparation : 
 
 3ml of reagent 1A was added to one bottle of reagent 1 and mixed gently by 
swirling till it dissolved completely. 
 
Sample Material : SERUM 
Procedure : 
 
  General System parameters. 
  The Instrument was set with the following parameters 
  Reaction type : Kinetic 
  Reaction slope : Increasing 
  Wavelength  : 405 nm 
  Flow cell temp. : 30oC 
  Delay time  : 60 sec 
  No.of Readings : 4 
  Internal  : 60 Secs 
  Sample vol.  : 100 µl 
  Reagent vol.  : 1 ml 
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  Path length  : 1 cm 
  Factor   : 11.11 
 
  Zero setting with distilled water. 
 
 A Test tube was taken. 1ml of reconstituted reagent was dispersed into it.  
Then 100µl of the test serum was added, mixed and read immediately. 
 
Linearity : 
  This method is linear upto 189u/l 
 
Reference  values : 
 
  Serum γ – Glutamyl Transferase : 
    Males  - 7-34 u/l (30oC) 
    Females - 4-25 u/l (30oC) 
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ESTIMATION OF GLUCOSE IN FASTING SERUM : 
 
Method : Glucose Oxidase – Peroxidase Method49 
Principle : 
 Glucose is oxidised to gluconic acid and hydrogen peroxide in the presence 
of glucose oxidase.  Hydrogen peroxide further reacts with phenyl and  4-amino 
antipyrine by the catalystic action of peroxidase to form a red colored quinonein 
dye complex. 
 
 Intensity of colour formed is directly proportional to amount  of glucose 
present in the sample. 
        
        Glucose Oxidase 
  Glucose + O2 + H2O        Gluconate + H2O2  
 
                                Peroxidase    
  H2O2  + 4  Amino antipyrine + Phenol         
             Red Quinoneine dye + H2O 
Reagent Contents : 
L1 : Glucose reagent : 4 x 250 ml 
L2 : Buffer reagent    : 10ml 
 
Glucose standard (100mg/dl) : 5 ml 
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Reagent Preparation : 
 
 2.5ml of Buffer reagent (L2) was added to 250ml of distilled water.  The 
contents of one bottle of Glucose reagent (L1) was emptied into it  and mixed by 
gently swirling and allowed to stand at room temperature for 30 minutes.  The 
working reagent is stable for 60 days when stored at 2-8oC. 
 
Sample Material :   Fasting Serum 
Procedure : 
 
  The  instrument was set with the following parameters 
  Reaction type  : End point 
  Reaction slope  : Increasing 
  Wavelength   : 505 nm 
  Incubation Temp.  : 37oC/R.T 
  Sample Vol.   : 10 minutes / 30 minutes 
  Reagent Vol.    : 1.0 ml 
  Standard concentration : 100 mg / dl 
  Zero setting with  : Reagent Blank 
  Linearity    : 500 mg /dl 
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  The reagent, distilled water standard and sample were pipetted into 
clean dry test tubes labeled as Blank (B), Standard (S) and Test (T) as following:- 
 
   
 
   
 
 
 
 All test tube contents were mixed well, incubated at 37oC for 10 minutes. 
The absorbance of standard (Abs.S), Test sample (Abs.T) were measured against 
blank within 60 minutes. At 505 nm (green filter). 
 
Calculation : 
 
  Total Glucose in mg/dl = Abs.T  
       x 100 
              Abs.S  
 
Linearity :  
 
  This procedure is linear upto 500mg/dl. 
Reference value :  
 
  Serum  : Glucose  Fasting level = 74-106mg/dl. 
Addition sequence B(ml) S (ml) T (ml) 
Working Reagent 1.0 1.0 1.0 
Distilled water 0.01 -- -- 
Glucose standard -- 0.01 -- 
Sample -- -- 0.01 
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ESTIMATION OF SERUM  TRIGLYCERIDES. 
Method : Enzymatic calorimetric method49. 
Principle : 
  Triglycerides + H2O Liproprotein lipase Glycerol + Fatty acid  
 Glycerol + ATP Glycerol Kinase   Glycerol – 3 – Phosphate+ ADP 
  Glycerol – 3 – Phosphate + O2 + GPO Dihydroxy acetene  
          Phosphate + H2O2 
  2 H2O2 + 4 – amino antiprine + ADPS Peroxidase  
     Red Quinone + 4 H2O  
  GPO = Glycerol – 3 – Phosphate Oxidase 
 
   ADPS = N-Ethyle – N – Sulfopropyl – n – aniside . 
 
 The intensity of purple coloured complex formed during the reaction is 
directly proportional to the trigylceride concentrate in the sample and is measured 
at 546 nm. 
 
Reagents : 
 
  Reagent 1 (Enzymes / Chromogen) 
  Lipoprotein Lipase   > or = 1100 u/L 
  Glycerol Kinase    > or = 800  u/L 
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  Glycerol – 3 – Phosphate Oxidase > or = 5000 u/L 
  Peroxides    > or = 300 u/L 
  4 – Amino antipyrine  > or = 0.7 mmol / L 
  ATP      > or = 0.3 mmol/L 
 
Reagent 1 A (Buffer) 
 
 Pipes Buffer, PH 7.50   50 mmol/L 
 ADPS      1 mmol/L 
 Magnesium Salt    15 mmol/L 
Standard (Triglycerides 200 mg/dL) 
 Glycerol (Trig. Equivalent)   2g/L 
 
Reagent Reconstitution : 
 
 The reagents are allowed to attain room temperature.  The contents of one 
bottle of reagent 1 were dissolved with one bottle of reagent 1 A, and mixed by 
gentle squirling and used for 5 minutes. 
 
 Reconstituted Reagent storage and stability.  The reconstituted reagent is 
stable for 6 weeks what stored at 2oC  - 8oC. 
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Procedure :- 
 
 The samples and the reconstituted reagent were brought to room 
temperature prior to use.  The instrument was set with the following parameters. 
General system parameters : 
 
 Reaction Type  : End point 
 Reaction Slope  : Increasing  
 Wave length   : 546 (520-570nm) 
 Flow cell Temperature : 30oC 
 Incubation   : 5 min at 37oC 
 Sample Volume : 10 µl 
 Reagent Volume : 1ml 
 Std. Concentration : 200 mg / dl 
Zero setting with  : Reagent Blank 
 
 The reconstituted reagent, standard and sample were dispensed into test 
tubes as follows : 
 
   
  
 
 Blank (ml) Standard 
(ml) 
Test (ml) 
Reconstituted Reagent 1 ml 1 ml 1 ml 
Standard --- 10 µl   
Sample   10 µl 
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 The test tubes are incubated at 37oC for 5 minutes.  Mixed well and read at 
546nm.  The final colour was stable for 30 minutes. 
 
Linearity : 
  The method is linear upto 1000 mg/dl. 
 
Reference value for Triglycerides 
 
  Serum / Plasma 
   Females  : 20 - 29 yrs   - 37 – 144mg/dl 
       30 – 39 yrs - 39 – 176mg/dl 
 
ESTIMATION  OF  SERUM CHOLESTEROL 
Method : Enzymatic Method49 
 Principle :     Cholesterol 
          Esterase  
  Cholesterol Ester + H2O      Cholesterol + Fatty 
acids 
  Cholesterol  + O2  Cholesterol Oxidase   Cholesterone + H2O2   
 
  2H2O + Phenol + 4 – Amino Antipyrine   
         Peroxidase    Red  Quinone + 4 – H2O 
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 The Concentration of Cholesterol in the sample is directly proportional to 
intensity of Red complex (Red Quinone) which is measured at 500 nm. 
 
Reagents :  
 
 
 Reagent 1 (Enzymes / Chromogen) 
 
 Cholesterol Esterase   ≥ 200 u/L 
 Cholesterol Oxidase   ≥ 250 U/L 
 Peroxidase    ≥1000 U/L 
 4- Amino Antipyrine  0.5 mmol/L 
 
Reagent 1 A (Buffer) 
 Pipes Buffer PH 6.90   50 mmol/L 
 Phenol    24 mmol/L 
 Sodium Cholate   0.5 mmol/L 
 
Standard (Cholesterol 200 mg/dl) : 
 
 Cholesterol     2g/L 
 
Storage and stability of the Reagents : 
 
  When stored at 2oC – 8oC and protected from light, the reagents are 
stable until expiry date on the labels. 
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Reagent  Reconstitution : 
 
 The reagents are allowed to attain room temperature.  The contents of 
one Bottle of reagents 1 were dissolved with one bottle of reagent 1A and mixed 
by gentle swirling. 
 
Reconstituted Reagent storage & Stability : 
 
 The reconstituted reagent is stable for 3 months when stored at 2oC – 8oC. 
 
Procedure : 
 
  The sample and reconstituted reagent were brought to room 
temperature. 
 
The instrument was set with the following parameters. 
 
 Reaction Type  : End point 
 Reaction Slope  : Increasing  
 Wave length   : 500nm (492-550nm) 
 Flow cell Temperature: 30oC 
 Incubation   : 5 min at 37oC 
 Sample Volume : 10 µl 
 Reagent Volume : 1.0ml 
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 Std. Concentration : 200 mg / dl 
Zero setting with  : Reagent Blank 
 
   The reconstituted reagent, standard and sample were dispensed into 
test tubes as follows;  
 
   
 The test tubes are incubated at 37oC for 5 minutes.  Mixed well and read at 
500nm.   
Linearity : 
 
  The method is linear upto 500 mg/dl. 
 
Reference value (Serum Cholesterol) 
  Serum / Plasma Cholesterol 
   Females  20 - 24 yrs  - 122-216 mg/dl 
     25 -  29 yrs - 128 – 222 mg/dl 
     30 – 34 yrs - 130 – 230 mg/dl 
 
 Blank (ml) Stan (ml) Test (ml) 
Reconstituted Reagent 1 ml 1 ml 1 ml 
Standard --- 10 µl  --- 
Sample --- --- 10 µl 
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Estimation of LDL CHOLESTEROL BY FRIEDWALD EQUATION 49 
 (LDL CHOLESTEROL) =  (Total Cholesterol – HDL Cholesterol)       – 
       Triglycerides   
         mg/dl 
       5 
 
  Reference Value : 
     Female : >130 mg/dl 
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ESTIMATION OF HDL – CHOLESTEROL  
 
Method : Phosphotungstate method49. 
Principle : 
 Chylomicrons, VLDL (Very low Density Liproprotein) and LDL fraction in 
serum are separated from HDL by precipitating with Phosphotungstic acid and 
Magnesium chloride.  After Centrifugation, the Cholesterol in the HDL fraction, 
which remains in the Supernatant, is assayed with enzymatic Cholesterol method, 
using Cholesterol esterase, Cholesterol Oxidase Superoxidase and the Chromogen 
4-Aminoantipyrin. 
 
Reagents : 
 
  Reagent 1 (Enzymes / Chromogen ) 
  Cholesterol Esterase   > or = 200 u / L 
  Cholesterol Oxidase   > or = 250 U/L 
  Peroxidase    > or = 10000 U/L 
  4 – Aminoantipyrin   .5 mmol / L 
 
Reagent 1 A  (Buffer) 
  Pipes Buffer, PH 6.9  50 mmol / L 
Phenol    24 mmol /L 
Sodium Cholate    0.5 mmol /L 
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Reagent 2 (Precipitating Reagent) 
 
 Phosphotungstic acid 2.4mmol /L 
 Magnesium chloride 39 mmol /L 
Standard (HDL Cholesterol 50mg/Dl) 
Cholesterol 0.5g/L 
 
Reagent Reconstitution : 
  The reagents are allowed to attain the room temperature.  The 
contents of one bottle of reagent 1 is dissolved into one bottle of reagent 1A, and 
mixed by gentle swirling till completely dissolved and used after 5 minutes.   
 
Reconstituted Reagent storage and stability : 
  The reconstituted reagent was stable for 3 months when stored at 
2oC - 8oC . 
 
Procedure : 
  The samples, precipitating reagent 2 and the reconstituted reagent 
were brought to room temperature prior to use. 
The instrument was set with the following parameters. 
 
General System Parameter: 
  Reaction Type   : End point 
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  Reaction Slope   : Increasing 
  Wave length   : 500 nm (492 – 550nm) 
  Flow cell temperature : 30oC 
  Incubation   : 5 minute at 37oC 
  Sample Volume   : 20 µl 
  (Supernatant) 
  Reagent Volume   : 1.0 ml 
  Std. Concentration  : 100mg /dl (The std of 50mg /dl is  
        to feel  as  100 mg/dl to account  
        for dilution of sample  in the  
        precipitation step) 
  Zero setting with  : Reagent Blank 
 
 
 
 
 
 
  The test tubes were incubated at 37oC for 5 minutes, mixed well and 
read at 500 nm. 
Linearity : 
  The method is linear upto 500 mg/dl. 
 Blank (ml) Standard 
(ml) 
Test (ml) 
Reconstituted Reagent 1 ml 1 ml 1 ml 
Standard --- 10 µl --- 
Sample --- --- 10µl 
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Reference Value (Serum Cholesterol) 
  Serum / Plasma Cholesterol  
   Female 20-24 yrs - 122 –216 mg/dl 
     25-29 yrs - 128 – 222 mg/dl 
30-34 yrs - 130-230 mg/dl. 
 
ESTIMATION OF URIC ACID : 
Method :  Enzymatic Method .(Caraway)49  
Principles : 
  Uric acid is converted by uricase into allantoin and hydrogen 
peroxide which in presence of peroxidase (POD/Oxidises the chromogen to a Red 
coloured compound which is read at 500 nm (492-550nm). The final colour of the 
reaction is stable for 15 minutes. 
 
  Uric acid + 2 H2O2 + O2 Uricase Allantoin + CO2 + H2O2 
 
  2 H2O2 + Aminoanipyrine PO D    Red quinone + H2O + Hcl  
    + DHBS 
  DHBS = 3.5 – Dichloro – 2 Hydroxybenzene Sulfonic acid  
  POD = Peroxidase. 
Reagents : 
  Reagent 1 (Enzymes / Chromogen) 
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  Uricase  > or = 60 U/L 
  Peroxidase > or = 660 u/l 
  4-Amino antipyrin  0.23 mmol/L 
 
Reagent 1A (Buffer) 
  Phosphate Buffer, PH 7.5   50 mmol /L 
  DAB 5    2 mmol /L 
 
Standard (Uric acid 6mg/dl) 
    Uric acid : 0.06g / L 
 
Storage and stability of the reagents : 
 
 When stored at 2oC – 8oC and protected from light, the reagent are stable 
until the expiry dates stated on the labels. 
 
Reagent Reconstitution : 
 The reconstituted reagent was stable for 4 weeks when stored at    2oC – 
8oC. 
 
PROCEDURE : 
  The sample and the reconstituted reagent were brought to room 
temperature. The instrument was set with the following parameters. 
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General system Parameters : 
 
  Reaction Type : End point 
  Reaction Slope : Increasing  
  Wavelength   : 510 nm (492 – 550nm) 
 Flow cell temp. : 30oC 
  Incubation  : 5 minutes at 37oC 
  Sample Vol.  : 25 µl  
  Reagent Vol.  : 1 ml 
  Std. Concentration : 6 mg/dl 
  Zero setting  with :  Reagent Blank. 
   
 The reconstituted reagent, standard and sample were dispensed into test 
tubes as follows.  
 
 
 
 
 
 The test tubes were incubated at 37oC for 5 minutes.  Mix well and read at 
510nm. 
 The final colour in stable for at least 15 minutes. 
 Blank (ml) Standard 
(ml) 
Test (ml) 
Reconstituted Reagent 1 ml 1 ml 1 ml 
Standard --- 25 µl 
 
--- 
Sample --- ---- 25 µl 
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Linearity : 
  The Method is linear upto 25 mg/dl. 
 
Reference Value in serum / Plasma : 
  Males  : 3.5 – 7.2mg/dl 
  Females : 2.6 – 6.0 mg/dl 
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ESTIMATION   OF  SERUM  AST 
Method : Kinetic Method49 
Principle : 
 L – Asparate + α – Keto Glutarate   GOT  Oxaloacetate + L Glutamate  
 
  
 Oxaloacetate + NADH + H + MDH L – Malate + NADH 
 
 AST = Aspartate transaminase + NAD + 
 MDH  = Malate Dehydrogenase 
 There is a decrease in absorption at 340 nm as NADH is converted to NAD. 
The rate of decrease in absorbance is measured and is proportional to AST activity 
in the sample. 
 
Reagents : 
Reagent 1 (Enzymes ) 
1. MDH   - > or = 600 u/L 
2. LDH   - > or = 900 u/L 
3. NADH  - 0.20 mmol / L 
4. α – Ketoglutarate  - 12 mmol /L 
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Reagent 1A (Buffer) : 
  Tris Buffer : Ph 7.80 88mmol /L 
  L – Asparatate   260 mmol /L 
 
Storage and stability of Reagents : 
 When stored at 2oC – 8oC and protected from light stable until expiry date 
on the label. 
 
Reconstitution of Reagents : 
 The contents of one bottle of Reagent 1 are dissolved with one bottle of 
Reagent 1A.  Mixed by gentle swirling.  The reconstituted reagent is stable for 4 
weeks when stored at 2oC – 8oC. 
 
PROCEDURE : 
 The samples and the reconstituted reagent must be brought to room 
temperature prior to use. 
 The instrument must be set with the following parameters. 
  General System Parameters : 
  Reaction Type : Kinetic  
  Reaction Slope : Increasing. 
  Wavelength   : 340 nm 
  Flow cell temp : 37oC 
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  Delay time  : 60 secs. 
  No.of Readings : 4 
  Interval  : 60 secs. 
  Sample Vol.  : 100 µl 
  Reagent Vol.  : 1.0 ml 
  Pathlength  : 1 cm 
  Factor   : 1746 
  Zero setting with : Distilled water 
 
 The reconstituted Reagent and sample are dispensed into the test tube, 
mixed and reading taken immediately.  
 
Linearity : 
 
  The method is linear upto 260 u/L 
 
Reference Values :  
 
  Serum / Plasma AST : Upto 46 U/L (at 370C) 
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ESTIMATION OF SERUM ALKALINE PHOSPHATASE 
Method : Kinetic Method 49 
Principle : 
 
  In buffered alkaline medium alkaline Phosphatase hydrolyse P-Nitrophenol 
which produces a yellow colour.  Intensity of the colour so produced is directly 
proportional to alkaline phosphatase activity and is measured photo metrically  at 
405 nm 
 
Reagents : 
Reagent 1 : DEA Buffer 
  Diethanolamine   1M 
  Magnesium Chloride  0.5 mM 
 
Reagent 2 : PNPP Tablets   
 Para Nitro Phenyl Phosphate  10 mM 
 
Reagent Reconstitution : 
 
  Each tablet in Reagent 2 is mixed with 2 ml of Reagent 1 mixed 
well, by gentle swirling to dissolve the tablet. 
 The reagent may be stored at 2oC – 8oC for 3 days in ambor coloured 
bottles. 
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Procedure : 
 The following parameters are set in the instrument. 
  Reaction Type  : Kinetic  
  Reaction Slope  : Increasing. 
  Wavelength    : 405 nm   
  Incubation time  : 60 secs. 
  Interval time   : 60 secs. 
  Interval No.   : 3 
  Factor    : 2713 
  Flow cell temp  : 37oC 
  Molar extinction Coefficient  : 18.7 
  ∆OD /mt Limit  : 0.55  
  Units    : 1U/L 
  Upper normal Value  : 810 U/L 
  Lower normal Value : 1101 U/L 
  Working Reagent Vol  : 1 ml 
  Sample Vol   : 100 µl  
  Reagent Vol   : 20 µl  
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 The reconstituted reagent and the sample are dispensed into the test tubes, 
mixed well and after 1 minute incubation absorbance is read,  photo metrically at 
405 nm at 37oC . 
 
Linearity : Upto 1500 Iu/L 
Reference Value :  
  Children  : 270 – 810 Iu/L 
  Adults  : 110 – 310 Iu/L 
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ESTIMATION  OF  SERUM  SGPT 
 
Method : 
 
 
 (Mod. IFCC method) For the determination of SGPT (ALT) activity in 
serum 49 
 
 
2. Principle : 
 
 
 SGPT (ALT) catalyzes the transfer of amino group between L-Alanine and    
α ketoglutarate  to form Pyruvate and Glutamate.  The Pyruvate formed reacts 
with NADH in the presence of Lactate Dehydrogenase to form NAD.  The rate of 
oxidation of NADH to NAD is measured as a decrease in absorbance which is 
proportional to the SGPT (ALT) activity in the sample. 
 
 L-Alanine + α ketoglutarate    SGPT        Pyruvate + L-Glutamate 
 
  Pyruvate + NADH + H+    LDH  Lactate + NAD+  
 
 
   
3. Reagents :     
 
 
L1 : Enzyme Reagent  20ml   60ml 
L2 : Starter Reagent    5ml   15ml 
 
 
Reagent Preparation  
 
 
  Reagent are ready to use. 
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Working reagent :  
 
 For sample start assays a singly reagent is required.  Pour the contents of 1 
bottle of L2 (Starter Reagent) into 1 bottle of L1 (Enzyme Reagent). This working 
reagent is stable for at least 3 weeks when stored at 2-8oC. Alternatively for 
flexibility as much of working reagent may be made as and when desired by 
mixing together 4 parts of L1 (Enzyme Reagent) and 1 part of L2 (Starter 
Reagent).  Alternatively 0.8ml of L1 and 0.2ml of L2 may also be used instead of 
1 ml of the working reagent directly during the assay. 
 
 
Sample material  
 
 
Serum : Free from hemolysis.  SGPT (ALT) is reported to be stable in serum 
for 3 days at    
   2-8oC. 
 
 
4.   Procedure : 
 
 
 Wavelength / filter : 340 nm 
 Temperature  : 37oC /30oC/25oC 
 Light path  : 1 cm 
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Substrate Start Assay : 
 
 Pippette into a clean dry test tube labeled as Test (T) : 
 
 
Addition Sequence
 
(T) 
25oC/30oC 
(T) 
37oC 
Enzyme Reagent (L1) 
Sample 
0.8 ml 
02 ml 
0.8ml 
0.1ml 
Incubate at the assay temperature for 1 minute and add 
Starter Reagent (L2) 0.2ml 0.2ml 
 
 Mix well and read the initial absorbance Ao & repeat the absorbance 
reading after every 1,2 & 3 minutes.  Calculate the mean absorbance change per 
minute (∆ A/min.) 
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ESTIMATION  OF  SERUM  UREA 
 
1. UREASE  METHOD  
 
Intended use  
 
 
 This reagent kit is intended for in vitro quantitative determination of Urea 
in serum or plasma49. 
 
Clinical Significance. 
 
 
 Urea is the main end product of protein metabolism.  Liver is the site of 
urea synthesis and urea is excreted by kidney. 
 
 Increases of serum or plasma urea concentration are associated with 
dehydration, shocks, fevers, acute glomerulonephritis and urine retention.  Low 
serum or plasma urea levels in clinical diseases such as severe liver damage due to 
viral hepatitis are rare. 
 
 
Principle. 
 
 
 This procedure is based on the Berthelot’s reaction.  Urease splits urea into 
ammonia and carbon dioxide.  The ammonia reacts with phenol in presence of 
hypochlorite to form an indophenol which with alkali gives a blue coloured 
compound.  The intensity of the colour is proportional to the concentration of urea 
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in the sample and is measured at 546nm (530-570nm). The colour of the reaction 
is stable for 8 hours. 
 
Sample Collection, Storage & Stability 
 
 
 Serum is preferred, plasma can also be used.  Anticoagulants such as 
heparin, Potassium oxalate, or EDTA can be used.  Ammonium salts and fluoride 
should not be used. Serum or plasma urea determination should be carried out as 
far as possible on the same day.  Samples are stable for a week when stored tightly 
capped at 2-8oC or for a month at – 10oC. 
 
Do not use hemolysed or grossly contaminated samples. 
 
 
3.    Reagents  
 
 
Reagent 1 (Urease) : 
Urease    > 1 KSU/L 
 
Reagent 1 A (Buffer) : 
 
Disodium EDTA  0.1 mol/L 
Sodium Nitroprusside   6 mmol/L 
 
Reagent 2 (Phenol) : 
Phenol   1.8  mmol/L 
 
Reagent 3 (Hypochlorite) : 
 
Sodium Hypochlorite 0.47 mol/L 
 
Standard (Urea 40mg/dL) : 
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Urea    0.4 g/L 
 
Reagent Reconstitution  
 
Allow the reagents to attain room temperature. 
 
 
Solution (1) 
 
 Transfer the contents of one bottle of reagent 1A into one bottle of reagent 
1.  Mix gently. 
 
Solution(2) 
 
 Add 77ml of distilled water into one bottle of reagent 2.  Mix gently. 
 
Solution (3) 
 
 Add 77mL of distilled water into one bottle of reagent 3.  Mix gently. 
 
RECONSTITUTED  REAGENT  STORAGE  &  STABILITY 
 
 When stored at a2-8oC, the reconstituted solutions 1,2,&3 are stable for 4 
months. 
 
Procedure : 
 
 The samples and the reconstituted solutions should be brought to the room 
temperature prior to use. 
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 The following general system parameters are to be used with this kit. 
 
General System  Parameters 
 
    Reaction Type  : Endpoint 
    Reaction Slope : Increasing  
    Wavelength  : 546 nm (530-570 nm) 
    Flowcell Temp. : 30oC 
    Incubation  : 10 Min. (1st step) &  
         15 min (2nd step) at 37oC 
    Sample Vol.  : 10 µL 
    Reagent Vol.  : 3.1 mL(Reagents 1+2+3) 
    Std. Concentration : 40mg/dL 
    Zero setting with : Reagent Blank 
 
Set the instrument using above system parameters.   
 
 
Dispense into test tubes: 
  
 Blank Standard Test 
Solution 1 100µ L 100µ L 100µ L 
Standard  -- 10µL -- 
Sample -- -- 10µL 
 
 
Incubate for 10 min. at 37oC. Mix and then add: 
 
    
Solution 2 1.5 mL 1.5mL 1.5 mL 
Solution 3 1.5 mL 1.5mL 1.5 mL 
 
Incubate for 15 min. at 37oC. Mix and read. 
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LINEARITY 
 
 
 The method is linear up to 200mg/dL. For high values, dilute the sample 
suitably with 0.9% saline and repeat the assay. Apply proper dilution factor to 
calculate the final result. 
 
REFERENCE  VALUES 
 
 
 It is recommended that each laboratory establish its own reference values.  
The following values may be used as a guideline: 
 
UREA : 
 
 Serum / Plasma : 10-50 mg/dL 
 
 
 
ESTIMATION OF SERUM CREATININE 
 
1. Method : Picrate Method49  CODE 746 1x50 mL 
747 2x50 mL 
748 4x50 mL 
  
2. Principle 
 
 Creatinine in alkaline solution reacts with picrate to form red-orange 
compound.  Under the specific conditions of the assay, the rate of development of 
the colour is proportional to the concentration of creatinine in the sample when 
measured at 500 nm (490-510nm). 
 
3. Reagents 
 
 Reagent a (Picrate) : 
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 Picric Acid    34.9 mmol/L 
 Sodium Hydroxide    45 mmol/L 
 
 Reagent 2 (Sodium Hydroxide) : 
 
 Sodium Hydroxide    0.26 mol/L 
 
 Standard (Creatinine 2 mg/dL): 
 Creatinine     0.020 g/L 
 
 
4.  Preparation of working solution 
 
 
 Allow  the reagents to attain room temperature.  Mix equal volumes of 
reagent 1 & reagent 2 in a clean beaker. 
5. Procedure 
 
 
 The samples and working  solution should be brought to room temperature 
prior to use.   
 
 The following general system parameters are to be used with this kit: 
 
 
    General  System Parameters 
 
 
   Reaction Type : Fixed Time 
   Reaction Slope : Increasing 
   Wavelength  : 500  nm (490-510nm) 
   Flowcell Temp.  : 25oC, 30oC or 37oC 
   Delay Time  : 30 secs. 
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   No.of Readings : 2 
   Interval  : 120 Secs 
   Sample Vol  : 100µ L 
   Reagent Vol.  : 1.0 mL 
   Path length   : 1 cm 
   Std. Concentration : 2 mg/dL 
   Zero Setting with : Distilled Water 
 
  Set the instrument using above system parameters. 
  
 
 
1. CALIBRATION  
 
 
   
  Dispense into test tube : 
 
 Standard 
Working Solution 1 mL 
Standard 100µL 
  
 Mix and read immediately for factor calculation. 
 
 
 
2. TEST 
 
 Dispense into test tube:  
 
 Standard 
Working Solution 1 mL 
Standard 100µL 
 
  Mix and read immediately. 
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LINEARITY 
 
 
 The method is linear up to 10 mg/dL. For higher values, dilute the sample 
suitably with .9% saline and repeat the assay.  Apply proper  dilution factor to 
calculate the final result. 
 
REFERENCE  VALUES : 
 
 
 It is recommended that each laboratory establish its own reference values.  
The following values may be used as a guideline : 
 
Creatinine : 
 
 Serum / Plasma 
 
 Females : 0.5 - 0.9 mg/dL
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RESULTS 
 
S.No. Gamma 
Glutamyl 
Transaferase 
(GGT) 
FBS  
Fasting 
Blood 
Sugar 
HDLC TGL TOTAL 
CHOLES- 
TEROL 
URIC 
ACID 
SGOT SGPT ALK. 
PHOSPH
. 
UREA CREA- 
TININE 
LDL AGE BMI B.P. 
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 
1 12.5 103 48 207 259 10.3 34.2 31 163.1 29 0.9 169.6 32 36.6 150/110 
2 26.3 111 37.6 179 255 6.9 31.5 24.4 227 21 0.6 181.2 45 28.5 140/90 
3 29.2 112 35 225 237 9.7 39.1 23.2 171 14 0.6 207 40 32.6 170/100 
4 28.00 102 40.4 206 308 7.8 39.7 30.3 209 25 0.8 225 48 34.6 134/90 
5 15 85 39.7 206 227 4.9 28.2 19.3 124 19 0.9 146.1 42 31.2 140/90 
6 29.9 92 42 190 235 6.8 36.3 24.3 172 22 0.9 155 52 30.8 136/100 
7 33.2 108 38.6 337 212 8.2 34.9 23.9 169 21 0.9 106.4 55 30.5 150/90 
8 13 84 43 140 235 4.4 29.8 18.00 184 21 0.7 164 45 29.56 134/100 
9 27.2 112 33.7 287 288 4.2 36.8 26.2 204 24 0.8 196.5 50 37.17 150/100 
10 30.7 137 29.1 231 219 10.6 32.5 22.9 112 28 1 144 65 37.4 140/80 
11 21.7 72 31.7 214 217 6.2 35.8 26.7 210 32 0.9 108 52 37.7 150/90 
12 30.1 108 38.6 202 186 6.6 26.7 18.6 147 20 0.9 152 55 35.4 136/90 
13 27.01 103 30 201 244 3.4 29.6 20.8 216 17 1.1 174 50 31.3 150/90 
14 25.5 85 37.6 245 219 5.8 29.2 24.3 216 15 0.8 132 37 32.7 180/110 
15 27.76 85 30.2 195 210 6.7 29.3 26.6 161 21 1 141 65 35.12 150/90 
16 19.72 79 42.6 186 207 9.2 30.6 23.4 164 30 0.7 127.4 65 33.78 150/90 
17 5.93 82 44.1 169 174 5.3 36.7 13.6 150 16 0.7 78 38 27.75 136/90 
18 25.58 75 38.2 186 220 4.3 27.3 18.6 143 19 0.9 111 65 30.1 140/90 
19 12.6 94 44.3 196 193 4.8 32.1 28.6 157 19 0.8 110 47 29.52 136/90 
20 28.2 84 42.3 183 226 5.1 31.6 28.4 156 30 0.8 142.6 50 30.1 160/100 
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(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 
 
21 29.6 101 38.4 187 204 6.2 29.3 27.6 147 16 0.8 127.8 55 32.90 140/90 
22 27.3 112 37.6 179 196 5.8 31.4 26.7 147 21 0.9 123 60 29.82 150/90 
23 18.1 95 42.3 182 167 4.3 38.67 30.1 212 18 0.7 88.6 55 30 150/100 
24 27.59 100 33.7 177 208 6.4 34.3 21.6 126 22 0.9 169 60 30.22 130/90 
25 23 92 40 204 193 5.2 37.1 30.9 162 17 0.6 112 58 27.62 140/90 
26 19.6 101 40.4 178 166 7.8 30.5 26.5 204 21 0.7 90 60 29.57 140/90 
27 37.3 123 36.3 239 251 8.8 29.3 29.1 156 28.5 1 166.9 72 34.28 136/90 
28 26.3 105 39.3 193 210 7.6 30.3 28.6 168 16 0.9 132.1 51 29.61 140/90 
29 34.3 76 40.2 192 196 6.0 39.1 18.9 155 17 0.9 128 57 32.00 140/100 
30 26.5 100 32.4 176 213 4.6 38 28.6 210 14 0.8 145.6 40 32.07 140/100 
31 27.1 101 40.6 189 201 5.8 42.1 28.4 169 19 1 132 60 29.58 150/100 
32 18.6 102 32.4 201 188 5.5 38.9 19.3 191 25 0.6 115.4 45 30.3 140/96 
33 32.5 105 28.3 190 198 5.8 40.1 23.4 148 15 0.8 172 62 43.55 140/96 
34 18.3 98 35.6 184 200 6.6 29.7 18.1 136 13 0.9 128 42 32.17 140/90 
35 28.9 102 46.1 179 203 5.8 29.3 19.8 192 19 0.7 142 49 35.00 136/90 
36 36.7 108 39.5 206 217 6.1 40.2 19.6 211 27 0.9 150 68 30.08 140/90 
37 34.2 106 37.8 213 241 7.3 32.1 19.6 169 18 0.6 160 50 33.84 140/100 
38 38.9 106 33.6 246 210 7.3 37.1 23.6 193 28.1 0.9 146 40 37.22 136/90 
39 26.2 96 39.1 198 207 7.5 31.6 24.1 166 27 0.8 138 52 29.82 150/100 
40 27.2 109 39.3 183 237 7.6 40.1 26.6 172 20 0.9 160 60 31.53 140/94 
41 14.7 99 41.3 177 193 4.9 34.6 29.1 177 20.6 0.8 118 45 30.66 136/90 
42 40.2 94 33.4 208 242 7.6 39.6 23.9 211 28 0.9 168 60 29.56 140/94 
43 22.3 103 39.4 200 230 8.7 29.6 19.2 159 22 0.8 136.2 56 32.52 180/100 
44 16.7 104 42.6 184 191 6.1 43.2 28.7 171 25.4 0.9 112 48 42.57 140/96 
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(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 
 
45 10.7 87 44.3 188 200 4.9 40.3 27.4 147 20.6 0.7 121.4 39 29.91 140/90 
46 29 106 40.2 196 238 6.6 33.6 28.7 193 18 0.7 148 42 30.76 150/100 
47 26.8 98 38.9 207 236 6.5 40.3 29.6 206 19.7 0.8 165 54 30.00 140/96 
48 38.3 103 36.2 224 239 6.8 35.8 23.1 241 30 1 188 46 30.75 140/94 
49 25.3 110 34.2 219 208 6 32.9 29.7 243 20 0.8 136 64 30.04 140/94 
50 26.68 94 43.1 197 240 6.8 31.6 29.3 184 15 0.8 157.2 47 31.62 136/90 
51 16.5 98 40.3 196 180 6.1 37.9 18.6 199 32 0.9 98.1 40 31.43 140/90 
52 23.6 109 38.9 188 221 6.3 41.6 25 193 26.3 1 144.5 60 34.34 140/100 
53 32.6 102 39.1 203 226 6.2 43.2 29.8 166 25 0.9 146.3 64 30.6 160/90 
54 21.3 105 39 200 197 5.9 39.7 21.6 211 20 0.9 118 52 30.90 150/96 
55 18.1 86 43.9 185 190 5.1 36.7 24.6 160 20 1 109.1 53 29.90 136/90 
56 19.97 101 42..4 180 202 6.6 44 27.1 20 24.1 0.8 123.6 45 30.90 140/94 
57 20.1 102 36.9 216 201 5.8 41.3 18.4 198 23 0.8 125.8 42 32.50 136/96 
58 30.3 109 39.7 248 242 8.7 34.3 27.6 210 23 1 152.7 65 32.26 140/90 
59 9.7 96 44.6 179 196 4.3 37.9 21.9 129 18 0.6 115.6 37 31.35 146/90 
60 7.37 89 48.6 180 186 4.8 32.2 18.8 171 35 0.8 101.4 42 35.82 136/100 
61 18.1 101 46 192 186 7.3 39 27.3 196 18.6 0.8 99 48 30 136/90 
62 25.6 100 40.6 188 222 9.3 38 25.9 181 19.6 0.9 143.8 50 31.5 136/96 
63 21.8 97 43.6 189 200 6.1 39.8 23.6 194 19.9 0.9 128.8 50 33.1 150/96 
64 28.1 110 40.1 215 255 7 38 26.7 147 20 0.9 172 52 32.8 170/100 
65 20.9 101 40 196 204 5.5 39.4 28 149 19.8 0.8 124.8 48 30.4 140/90 
66 25.9 104 39.6 194 222 6.2 34.3 26.1 182 20 0.8 143.6 44 35.4 140/96 
67 22.1 102 43 186 194 5.4 39.7 23.4 169 19 0.9 123.8 50 30 146/96 
68 17.6 84 44.6 179 206 6.9 34.7 31 127 16 0.7 125.6 46 30.02 140/90 
69 29 106 37.9 210 240 6.4 42.6 29.6 210 26 1 160.1 60 31.4 150/100 
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(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 
 
70 31.8 107 40.6 204 222 8.4 34.9 29.1 196 32 1 140 55 32.91 150/100 
71 43.3 100 35.3 198 261 10.7 33.5 28.6 193 27 0.7 186.1 53 36.66 150/100 
72 25.6 89 38.6 192 207 6.6 43.1 26.7 196 21 0.7 134 57 30.22 140/96 
73 14.9 103 42.6 177 191 6.2 42.6 30.1 181 16 0.7 113 51 29.62 140/90 
74 20.9 98 45.1 177 193 7 42.6 23.9 147 20 0.8 122.5 43 31.11 136/86 
75 27.36 89 30.76 198 232 9.1 34.9 20.8 216 24.6 1 161.8 61 32.10 160/100 
76 40.3 107 39.7 261 243 7.3 41.9 27.6 193 30.1 0.9 152 49 34.16 150/100 
77 24.7 108 40.5 193 204 6.3 39.1 31 151 28 0.9 140 65 30.47 140/96 
78 18.9 104 42 190 202 5.8 36.3 24.1 158 21.6 0.7 122 43 30.86 140/100 
79 28.3 108 42.1 196 206 8.6 36.7 29.8 184 20 0.9 146.4 55 31 170/100 
80 27.6 103 38.9 198 216 7.1 38.1 29.1 149 30.1 1 142.5 58 34.28 160/100 
81 17.94 92 44.6 189 194 6.7 41.9 29.4 206 23.6 0.9 116 56 30.01 150/90 
82 23.3 84 42.2 201 212 4.7 30.7 27.6 193 17.9 0.7 134 39 31 136/90 
83 15.6 98 41.9 179 190 4.3 37.9 28.1 210 18.6 0.6 112.3 51 30 130/90 
84 20.5 96 44 178 200 4.1 42.1 26.6 170 16.5 0.7 120.4 41 30.02 136/90 
85 20.1 108 44.5 212 195 5.9 40.6 20.4 191 27 0.9 138 40 33.33 136/96 
86 19.6 94 35.7 197 222 6.4 38 24.6 179 29 0.8 127 65 32.03 154/100 
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(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 
 
87 29.1 102 40.9 204 219 6.3 43.1 20.6 203 28 0.9 168 62 30.26 150/90 
88 26.4 100 42 199 244 6.8 36.1 21.9 173 20.3 0.7 163.4 40 33.30 140/96 
89 28.9 96 37.5 259 227 7.8 31.7 19.6 149 28 0.8 170 55 34.75 160/94 
90 18.7 86 49 180 190 6.1 34.6 18.1 173 30 0.8 98 52 31.5 170/90 
91 21.6 103 42.1 197 206 5.8 36.6 29.9 167 21 0.9 126.5 42 34.66 150/90 
92 30.1 106 40 204 237 6.8 37.6 29.8 112 24 0.8 156.2 48 40 140/100 
93 23.6 104 41.7 200 206 7.1 42.6 21.9 143 25 0.8 136.3 51 34 146/90 
94 26.8 96 39 217 224 7 42 28.8 161 22.1 1 15.6 65 33.91 150/100 
95 17.9 101 44.1 179 196 6.7 42 28.9 182 22.4 0.8 117 57 30 140/94 
96 26.2 103 39.4 196 231 6.1 40.7 27.6 201 19.6 0.8 152.8 49 34.27 150/100 
97 36.2 106 40 230 245 10.1 32.9 26.7 191 30.1 1 159 56 34.63 140/100 
98 18.1 98 42 200 187 5.8 38.7 27.3 194 19 0.9 105 40 30.47 140/96 
99 17.8 80 46 186 192 4.9 39.6 18.9 171 16 0.8 109 42 30.90 136/90 
100 35.4 101 38.7 201 247 6.6 40.6 30.1 147 21 0.9 158.3 58 30 140/94 
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Table : 1 
 
DISTRIBUTION OF VARIABLE CLASSES IN THE POPULATION 
STUDIED 
 
GGT AGE FBS URIC ACID HDLC TOTAL CHOLESTROL
Class Frq. Class Frq. Class Frq. Class Frq. Class Frq. Class Frq.
4.5-9.9 2 30-34 1 70-79 4 3.0-3.9 1 28.5-30.9 5 160-179 3 
10.0-14.9 7 35-39 5 80-84 6 4.0-4.9 15 31.0-33.4 4 180-199 25 
15.0-19.9 19 40-44 18 85-89 9 5.0-5.9 18 33.5-35.9 8 200-219 33 
20.0-24.9 17 45-49 17 90-94 7 6.0-6.9 36 36.0-38.4 11 220-239 22 
25.0-29.9 36 50-54 20 95-99 14 7.0-7.9 16 38.5-40.9 35 240-259 14 
30.0-34.9 10 55-59 16 100-104 32 8.0-8.9 6 41.0-43.4 19 260-279 1 
35.0-39.0 6 60-64 13 105-109 20 9.0-9.9 4 43.5-45.9 12 280-300 1 
40.0-45.0 3 65-70 10 110-115 8 10.0-10.9 4 46.0-48.5 6 300-320 1 
 
TGL LDL BMI CREATININE 
Class Frq. Class Frq. Class Frq. Class Frq. 
149-169 2 60-79 1 24.0-26.4 1 0.6 7 
170-184 22 80-99 5 26.5-28.9 2 0.7 16 
185-199 36 100-119 18 29.0-31.4 50 0.8 29 
200-214 22 120-139 27 31.5-33.9 22 0.9 33 
215-229 7 140-159 27 34.0-36.4 15 1.0 14 
230-244 3 160-179 16 36.5-38.9 7 1.1 1 
245-259 4 180-199 4 39.0-41.4 1   
260-275 4 200-219 2 41.5 2   
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Variability for characters in the Population Studied 
Table : 2 
Range S.No. Character Population 
Size Min. Maxi.
Mean Standard 
Error 
(Mean) 
Standard 
Deviation 
Coefficient 
of 
variation 
(CV%) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
GGT 
FBS 
HDLC 
TGL 
T.Chl. 
Uric Acid 
SGOT 
SGPT 
Alk. Phosp. 
Urea 
Creatin 
LDL 
Age  
BMI 
B.P.(S) 
B.P.(D) 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
 
5.9 
72.0 
28.3 
140.0 
166.0 
3.4 
26.7 
13.6 
112.0 
13.0 
0.6 
78.0 
32.0 
25.5 
130.0 
86.0 
43.3 
137.0 
49.0 
337.0 
308.0 
10.7 
44.0 
31.0 
243.0 
35.0 
1.1 
225.0 
72.0 
43.6 
180.0 
110.0 
24.64 
99.21 
39.74 
199.97 
215.05 
6.53 
36.41 
25.16 
176.98 
22.19 
0.83 
138.87 
51.42 
32.20 
144.54 
94.44 
 
0.74 
1.01 
0.42 
2.53 
2.44 
0.15 
0.45 
0.41 
2.75 
0.49 
0.01 
2.63 
0.86 
0.30 
1.00 
0.50 
 
7.38 
10.06 
4.20 
25.30 
24.44 
1.49 
4.50 
4.10 
27.51 
4.93 
0.12 
26.30 
8.59 
2.95 
10.01 
4.95 
30.00 
10.14 
10.57 
12.65 
11.36 
22.77 
12.35 
16.31 
15.59 
22.21 
13.76 
18.90 
16.70 
9.16 
6.92 
5.24 
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Table : 3 Partial Correlations – Exclusion of variables. 
 
Model 
No 
Variable Beta’ 
in 
‘t’ Significant 
Level 
Partial 
correlation 
(PC) 
1 FBS 
T.Chol 
TGL 
Creatin 
BMI 
Uric Acid 
Age 
0.176 a 
0.021 a  
0.332 a  
0.246 a 
0.066 a 
0.251 a 
0.376 a 
2.095 
0.132 
4.334 
3.197 
0.792 
3.048 
5.301 
0.039* 
0.895NS 
0.006** 
0.002** 
0.430NS 
0.003** 
0.000** 
0.208 
0.013 
0.403 
0.309 
0.080 
0.296 
0.474 
2 FBS 
T.Chol 
TGL 
Creatin 
BMI 
Uric Acid 
0.120 b 
0.047 b 
0.300 b 
0.166 b 
0.068 b 
0.164 b 
1.584 
0.342 
4.425 
1.515 
0.926 
2.136 
0.116 NS 
0.733 NS 
0.000* 
0.133 NS 
0.357 NS 
0.036* 
0.160 
0.035 
0.412 
0.153 
0.094 
0.212 
3. FBS 
T.Chol 
Creatin 
BMI 
Uric Acid 
0.044 
0.132 
0.053 
0.007 
0.097 
0.604 
-0.983 
0.733 
0.100 
1.330 
0.547 NS 
0.323 NS 
0.465 NS 
0.920 NS 
0187 NS 
0.062 
0.101 
0.075 
0.010 
0.135 
 
Influenced variable   : GGT 
 
a. Predictors in Model 1 : (Constant), LDL 
b. Predictors in Model 2 : (Constant), LDL, Age 
c. Predictors in Model 3 : (Constant), LDL, Age, TGL 
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Table : 4  Correlation (r) among variables (Pearson’s) 
 
 FBS HDLC TGL T.CL. Uric 
Acid 
SGOT SGPT Alk. 
Pho. 
Urea Creatin LDL Age BMI BPS BPD 
GGT 0.383** -0.528** 0.487** 0.538** 0.449** -0.051 0.134 0.151 0.193 0.338** 0.618** 0.449* 0.238* 0.146 0.144 
FBS  -0.270** 0.346** 0.259** 0.380** 0.116 0.212* 0.045 0.113 0.194 0.374** 0.182 0.212* -0.001 0.041 
HDL   -0.345** -0.308** -0.167 0.160 0.062 -0.127 -0.022 -0.246* -0.423** -0.363** -0.261** -0.107 -0.038 
TGL    0.400** 0.323** -0.047 0.042 0.133 0.242* 0.260** 0.298** 0.122 0.273** 0.253* 0.118 
T.Chl.     0.375** -0.110 0.194 0.156 0.203* 0.162 0.861** 0.092 0.231* 0.179 0.309** 
Uric  
Acid 
     -0.092 0.142 -0.031 0.334 0.208* 0.378** 0.270** 0.263** 0.243* 0.176 
SGOT       0.237* 0.168 0.072 0.022 -0.057 -0.005 -0.010 -0.061 0.086 
SGPT        0.099 -0.023 0.055 0.100 0.157 0.020 0.026 0.116 
Alk. 
Pho 
        0.135 0.015 0.127 -0.022 -0.171 0.035 0.180 
Urea          0.335** 0.122 0.248* 0.280** 0.130 0.148 
Crea-
tin 
          0.159 0.402** 0.221 0.110 0.044 
LDL            0.129 0.288** 0.130 0.277** 
Age             0.032 0.111 -0.111 
BMI              0.085 0.242* 
BPS               0.441** 
 
   BPD     N  = Population size = 100 
        *  = Correlation Significant at 0.05 level 
        ** = Correlation significant at 0.01 level. 
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Table : 5 
 
 
χ2 Test for independence between GGT and other variables  
(Summary) 
 
 
Grouping based on Clinically normal levels Grouping based on sturges rule with 
combination of marginal classes 
S.No. 
Variables d.f χ2 ‘P’ 
level 
Coeff. Of 
Mean 
square 
contingency
d.f χ2 ‘P’ 
level 
Coeff. Of 
Mean 
square 
contingency
1. 
2 
3 
4 
5 
6 
7 
8 
9 
 
GGT-FBS 
GGT-TGL 
GGT-T.Chol. 
GGT-Uric Acid 
GGT-Creatinine 
GGT-Age 
GGT-BMI 
GGT-LDL 
GGT-HDLC 
1 
1 
1 
1 
1 
1 
1 
1 
1 
8.09 
5.06 
31.87
10.71
5.73 
7.20 
3.90 
48.54
23.71
0.005 
0.025 
0.0001 
0.001 
0.025 
0.010 
0.05 
0.0001 
0.0001
0.274 
0.219 
0.492 
0.311 
0.233 
0.259 
0.194 
0.572 
0.438 
4 
4 
4 
4 
4 
3 
6 
6 
4 
 
12.82 
19.26 
38.48 
25.68 
10.67 
12.33 
17.12 
48.18 
13.33 
0.020 
0.001 
<0.001 
<0.001 
0.050 
0.025 
0.010 
<0.001 
0.010 
0.337 
0.402 
0.527 
0.452 
0.311 
0.331 
0.382 
0.570 
0.343 
 
 
 
 
    N = 100 
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STATISTICAL  ANALYSIS 
Table – 6 (a) 
 
 Age and GGT Positivity 
 
  
 
 
 
 
 
 
 
     DF   = 3 
 
     χ2 = 12.33    
 
 Significant at level of P=0.025 
  coefficient of mean square contingency = 0.331 
 
* * * * *     * * * * *    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE 
 
GGT 
30-39 Yrs. 40-49 
Yrs. 
50-59 
Yrs 
≥ 60 
Yrs. 
TOTAL
15-25 5 21 14 5 45 
≥ 25 1 14 22 18 55 
TOTAL 6 35 36 23 100 
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Table – 6 (b) 
 
 Age and GGT Positivity 
 
  
 
 
 
 
 
 
 
     DF  = ( 2 – 1) (2-1) 
      = 1 = 1 
 
     χ2 = 7.20   
 
   Significant of P= 0.010 level 
  Coefficient of mean square contingency = 0.259 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE 
 
GGT 
≤ 44 yrs ≥ 45 Yrs TOTAL
≤ 25 17 28 45 
> 25 7 48 55 
TOTAL 24 76 100 
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Table – 7(a) 
 
 GGT and Fasting Blood Sugar levels 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = (3-1) (3-1) 2x2 = 4 
   χ2 = 12.82 
  Significant at P= 0.020 level 
  CMSC  = 0.337 
 
Fasting  
    Blood  
              Sugar 
 
GGT 
70-90 
mg/dl 
91-100 
mg/dl 
100-120 
mg/dl 
TOTAL 
Upto 15 2 5 2 9 
15-25 5 14 17 36 
≥ 25 3 11 41 55 
 10 30 60 100 
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Table – 7(b) 
 
 GGT and Fasting Blood Sugar levels 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = (2-1) (2-1) = 1x1=1 
   χ2 = 8.09 
 
  Significant at P= 0.005 level 
 
Fasting  
    Blood  
              Sugar 
 
GGT 
≤106 
mg/dl 
≥107 
mg/dl 
TOTAL
≥ 25 42 3 45 
>25 39 16 55 
TOTAL 81 19 100 
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Table – 8(a) 
 
 GGT and Uric acid levels 
   
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = 4 
   χ2 = 25.68 
 
  Significant at P< 0.001 level 
  CMSC  = 0.452 
 
 
* * * * *     * * * * *    
 
Uric 
            Acid  
               
GGT 
<5mg/dl 5-7 mg/dl >7mg/dl TOTAL 
<15 6 2 1 9 
15-25 6 24 6 36 
> 25 4 28 23 55 
TOTAL 16 54 30 100 
 68
 
 
 
 
 
 
 
 
 
Table –8(b) 
 
 GGT and Fasting Uric Acid levels 
 
   
 
 
 
 
 
 
 
 
 
 
 
   D.F = 1 
   χ2 = 10.71 
 
  Significant at P= 0.001 level 
  Coefficient of mean square contingency = 0.311 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uric  
       Acid 
  GGT 
≤ 6 mg/dl >6 mg/dl TOTAL
≤ 25 24 21 45 
≥ 25 11 44 55 
TOTAL 35 65 100 
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Table – 9(a) 
 
 GGT and Low Density Lipoprotein  
 
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = (4-1) x (3-1) = 3x2=6 
   χ2 = 48.18 
 
  Significant at P< 0.001 level 
  CMSC  = 0.570. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDL 
               
GGT 
<5mg/dl 5-7 mg/dl >7mg/dl TOTAL 
≤15 6 1 2 9 
15-25 29 6 1 36 
25-35 5 25 16 46 
35-45 1 4 4 9 
TOTAL 41 36 23 100 
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 Table – 9(b) 
 
 
 GGT and Low Density Lipoprotein levels 
 
   
 
 
 
 
 
 
 
 
 
 
 
   D.F = 1 
   χ2 = 48.54 
 
  Significant at P= 0.0001 level 
  Coefficient of mean square contingency = 0.572 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           LDL 
 
  GGT 
≤ 130 
mg/dl 
>130 
mg/dl 
TOTAL
≤ 25 36 9 45 
> 25 5 50 55 
TOTAL 41 59 100 
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Table – 10(a) 
 
GGT and High Density Lipoprotein  
  
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = 4 
   χ2 = 13.33 
 
  Significant at P= 0.010 level 
  CMSC  = 0.343 
 
* * * * *     * * * * *    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HDL-C 
               
GGT 
≤33.5 33.6 – 
38.4 
≥38.5 TOTAL 
≤25 2 3 40 45 
25-35 6 12 28 46 
35-45 1 4 4 9 
TOTAL 9 19 72 100 
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Table– 10 (b) 
 GGT and High Density Lipoprotein levels 
 
  All within the normal level, Hence population mean level was taken as the 
point of division for HDLC 
 
 
 
 
 
 
 
 
 
 
   D.F = 1 
   χ2 = 23.71 
 
  Significant at P= 0.0001 level 
  Coefficient of mean square contingency = 0.438 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        HDL-‘C’ 
 
  GGT 
≤ 
39.72mg/dl
>39.73mg/dl TOTAL
≤25 9 36 45 
> 25 39 16 55 
TOTAL 48 52 100 
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Table – 11(a) 
 
 GGT and Total Cholesterol levels 
   
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = 4 
   χ2 = 38.48 
 
  Significant at P<0.001 level 
  CMSC  = 0.527 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Cholesterol   
               
GGT 
160-200 
mg/dl 
200-240 
mg/dl 
>240mg/dl TOTAL 
≤15 7 1 1 9 
15-25 21 14 1 36 
> 25 4 35 16 55 
TOTAL 32 50 18 100 
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Table  11 (b) 
 
 GGT and Total Cholesterol levels 
 
   
 
 
 
 
 
 
 
 
 
 
 
   D.F = 1 
   χ2 = 31.87 
 
 
  Significant at P= 0.0001 level 
  Coefficient of mean square contingency = 0.492 
 
 
 
 
 
 
 
 
 
 
Total  
                  Cholesterol 
 
  GGT 
150-200 
mg/dl 
≥201 
mg/dl 
TOTAL 
≤ 25 28 17 45 
≥ 25 4 51 55 
TOTAL 32 68 100 
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Table – 12(a) 
 
 GGT and Triglyceride level : 
   
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = 4 
   χ2 = 19.26 
 
  Significant at  P= 0.001 level 
  CMSC  = 0.402 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Triglyceride 
               
GGT 
≤185mg/dl 185-215 
mg/dl 
216-245 
mg/dl 
TOTAL 
≤15 6 2 1 9 
>15-25 11 23 2 36 
> 25-45 70 32 16 55 
TOTAL 24 57 19 100 
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Table – 12(b) 
 
 GGT and Triclycerides levels 
 
  Population mean taken of the point of class separation for TGL 
   
 
 
 
 
 
 
 
 
 
 
 
   D.F = 1 
   χ2 = 5.06 
 
  Significant at P= 0.025 level 
  CMSC = 0.219 
 
 
 
 
 
 
 
 
 
 
 
           TGL 
 
  GGT 
≤ 
199.97mg/dl
≥199.98 
mg/dl 
TOTAL
≤ 25 33 12 45 
> 25 27 28 55 
TOTAL 60 40 100 
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Table – 13(a) 
 
 GGT and Serum Creatinine  level : 
   
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = 4 
   χ2 = 10.67 
 
  Significant at P= 0.050 level 
  CMSC  = 0.311 
 
 
 
 
 
 
 
 
 
 
 
 
      
Creatinine 
               
GGT 
≤0.7mg/dl 0.8-0.9 
mg/dl 
1-1.1 
mg/dl 
TOTAL 
≤25 15 28 2 45 
26-35 7 29 10 46 
36-45 1 5 3 9 
TOTAL 23 62 15 100 
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Table – 13(b) 
 
 GGT and Creatinine levels 
 
   
 
 
 
 
 
 
 
 
 
 
 
   D.F = 1 
   χ2 = 5.73 
 
  Significant at P= 0.025 level 
  Coefficient of mean square contingency = 0.233 
 
 
 
 
 
 
 
 
 
 
 
 
        Creatinine 
 
  GGT 
0.5-0.9 
mg/dl 
>1 mg/dl TOTAL 
< 25 43 2 45 
> 25 42 13 55 
TOTAL 85 15 100 
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Table – 14  (a) 
 
 GGT and Serum Body Mass Index  level : 
   
 
 
 
 
 
 
 
 
 
 
 
 
   D.F = (4-1) x (3-1) = 3x2 = 6 
   χ2 = 17.12 
 
  Significant at P= 0.010 level 
  CMSC  = 0.382 
 
 
 
 
 
 
 
 
 
 
 
 
 
     BMI    
            
GGT 
≤ 29 30-34 ≥ 35 TOTAL 
5-15 5 2 2 9 
15-25 9 22 5 36 
25-35 5 28 13 46 
35-45 2 2 5 9 
TOTAL 21 54 25 100 
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Table – 14(b) 
 
 GGT and Body Mass Index levels 
 
     
 
 
 
 
 
 
 
 
 
 
 
   D.F = 1 
   χ2 = 3.90 
 
  Significant at P= 0.05 level 
  Coefficient of mean square contingency = 0.194 
           BMI 
 
  GGT 
≤ 30 mg/dl >30 mg/dl TOTAL
≤ 25 16 29 45 
> 25 9 46 55 
TOTAL 25 75 100 
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DISCUSSION 
 
 Gamma – Glutamyl Transferase is a cell-surface protein contributing to 
exracellular catabolism of Glutathione50, the main thiol antioxidant in humans.  
The enzyme is produced in many tissues but serum GGT is derived mainly from 
Liver50. 
 
  GGT is carried primarily by lipoproteins and albumin 51.  Serum levels of 
GGT are determined by factors like body fat, plasma lipid/lipoproteins, glucose 
levels, alcohol intake etc. 
 
 In my study conducted among 100 females with features of metabolic 
syndrome, 55 percent of them showed an increase in Serum GGT levels, and 45 
percent were within normal limits.  It was found that serum GGT had a positive 
and strong association with,  
 
a. Age 
b. Low Density Lipoprotiens 
c. Triglycerides 
d. Total cholesterol  
e. Body Mass Index  
f. Fasting Blood Sugar 
g. Uric Acid 
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  Metabolic syndrome can be considered a coronary artery disease 
equivalent52. Multiple pathophysiological mechanism play a role in the increased 
risk of cardiovascular events in the metabolic syndrome. These mechasims include 
hypertension, dyslipidemia etc. 
 
  In the present study, which included female patients of three different 
religions – Hindus, Muslims and Christians, trends indicate differences among 
these groups for the important risk factor LDL. The mean values for LDL is 
highest among Muslims (152.82mg/dl) and  least among Christians (125.60mg/dl).  
Among Hindus it was (137.80mg/dl) next to Muslims with very close  association 
to the population mean of 138.87 
  
 The levels of HDL cholesterol were converse, highest among Christians 
(40.48), among Hindus it was (39.86) and the lowest  among Muslims (38.26). 
 
 Atherogenic dyslipdemia is an integral component of the metabolic 
syndrome and is a major contributor to the cardiovascular risks. In these patients 
an abnormal lipid profile is a more significant risk factor than either hypertension 
(or) diabetes mellitus alone.  The typical lipid abnormalities defined in patients 
with metabolic syndrome consists of  a triad: 
1. Increased LDL Cholesterol 
2. Increased Triglycerides 
3. Decreased HDL Cholesterol 
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  The small dense LDL particles are more atherogenic because they are more 
susceptible to oxidation53. The formation of early lesions of atheroscelerosis most  
often arise from focal increases in content of lipoprotein within regions of intima 
of arteries because they bind to constituents of extracellular matrix increasing  the 
residence time of lipid rich particles with arterial wall.  Lipoproteins which 
accumulate in the extracellular space of intima of arteries associate with         
proteoglycon  of arterial extra cellular matrix and become susceptible to oxidative 
modification. 
 
  In our study, LDL showed the highest positive correlation with GGT at a 
level of (P=0.0001). 59 percent showed serum LDL levels greater than 130mg/dl. 
Similarly, age of the patients included in the study ranged from thirty two to 
seventy two years and showed positive correlation with GGT at a significant level  
of (P=0.001). Study results revealed increased  levels of GGT with increase in age 
groups especially between forty to sixty years. But in Muslims the average age 
group was much lower and the risk set at an younger age compared to Hindus and 
Christians. 
 
 Similarly, GGT levels showed a strong positive correlation with serum 
triglycerides significantl at a ‘P’ value of (0.001).  The mean triglycerides levels 
were highest among Muslims (217mg/dl), followed by Hindus (198.21mg/dl) and 
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(187.44mg/dl) among the Christians, probably due to varied intake of non-
vegetarian diet. 
 
  Insulin normally suppresses the Production of VLDL particles from Liver.  
This effect is due to increase in free-fatty acid availability following Insulin 
inhibition of lipolysis in adipose tissue, and a direct hepatic effect of Insulin, 
inhibiting the production of VLDL particles. The intrahepatic defect appears to 
major contributory mechanisms underlying the increase in serum triglycerides in 
insulin resistance condition. 
 
  HDL levels are reduced in Insulin resistance patients54 with high serum 
triglycerides. Under hypertriglyceridemic conditions there is excessive exchange 
of cholesterol esters and triglycerides between HDL and expanded pool of 
triglyceride rich lipoproteins mediated by the cholesterol ester transfer protein 
(CETP). HDL becomes enriched with triglycerides and acts as a good substrate for 
hepatic lipase which removes HDL at an accelerated rate. In my study, Pearson’s 
method of correlation indicated negative correlation of HDL-C and GGT at           
(-0.528), which is highly significant negative correlation. 
 
 The mean body mass index (BMI) in my study was (32.20),  with Hindus 
(31.95) Christians (32.04) and Muslims (33.69).  Again body mass index is highest 
among the Muslim women and are more prone for increased GGT levels and 
hence coronary heart disease. Though, 50 percent of the females showed BMI 
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values between (29-31.4), 2 percent showed very high values of BMI about 
(41.50).  GGT and BMI were significant with positive correlation at (P=0.05) 
level. 
 
 In obesity particularly visceral (or) central, adipocytes secrete number of 
biologicalproducts like Tumor Necrosis factor – alpha, free fatty acids, 
adiponectin,  leptin and interleukin-6 that modulate insulin secretion, insulin 
action, body weight and contribute to insulin resistance. These biological 
substances secreted by adipocytes increase the amount of inflammation which can 
cause build up of plagues in vesselwalls.  Eventually pieces of clots can break up 
and block blood vessels leading to myocardial infarction. 
 
 Persons with metabolic syndrome have a three fold greaser risk of coronary 
heart disease and four fold risk of cardiovascular mortality. The growth in 
prevalence of metabolic syndrome parallels the dramatic rise in Prevalence of 
obesity.55,56 
 
 In my study about 33 percent shown serum cholesterol levels between  
200-219mg/dl and 25 percent showed 180-199mg/dl. 3 percent showed levels 
greater than  260mg/dl.  The mean fasting blood sugar was 100-104mg/dl in 32 
percent, 105-109mg/dl in 20 percent and 110-115mg/dl in 8 percent and  
70-99mg/dl in 40 percent. GGT was positively correlating with fasting blood sugar 
at (P=0.0005) level. 
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 The mean systolic blood pressure was 144.54 mm.Hg, ranging from 
maximum of 180mm.Hg and minimum of 130mm.Hg.  The mean diastolic blood 
pressure was 94.4mm of Hg with a maximum of 110mm of Hg to a minimum  86 
mm.of Hg 
 
OBESITY              Insulin  
      Resistance 
 
 
 
 
   ATHEROSCLEROSIS 
 
 
  ENDOTHELIAL DYS FUNCTION  
 
 An integral component of metabolic syndrome is blood pressure greater 
than 130/85 mm of Hg.  Insulin resistance and hyperinsulinemia contribute to 
increased propensity for development of hypertension.  Direct effect of elevated 
insulin on sympathetic nervous system activity can lead to elevated blood 
pressure. 
Hypertension 
Hyper Insulinemia 
Hyper Triglycerides 
Increased LDL 
LOW HDL
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 In hypertensive patients, increased local formation of Angiotensin II in 
adipose tissues was noted 55 and therefore there exists close relationship between 
Angiotensin II and Insulin resistance. 
 
 The mean serum uric acid level was (6.53 mg/dl) in my study, with a 
maximum of (10.70 mg/dl) to a minimum of (3.41mg/dl).  Many females, about 
36 percent had serum uric acid levels between (6.00 – 6.90 mg/dl). GGT  and  uric 
acid  showed  positive correlation at (P=0.001) level. 
 
 The major component of metabolic syndrome 56 is insulin resistance, which 
influences protein metabolism, uric acid, an end product of protein metabolism is 
elevated.  In Patient with metabolic syndrome , excretion of uric acid via kidney is 
also impaired . 
 
 In this study the mean, serum GGT level was (24.64) units/litre with 
maximum of (43.32) units/litre end a minimum of (5.90) units/litre.  Among this, 
46 percent showed high values of GGT ranging from (25.10 to 35.00) units/lit and 
9 percent showed very high values (35.10 to 45.00) units /litre. 
 
 Eventhough  GGT is expressed in several tissues, the main source of serum 
GGT is the Liver57.  GGT’s central role is in intrecellular glutathione homeostasis 
and extracellular glutathione metabolism. It enhances hydrolysis of gamma-
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glutamyl bond of glutathione releasing dipeptide cysteinyl-glycine which outside  
the cell reduces Fe3+  to Fe2+   and releases a free thyolyl radical.  This released free 
radical 58 oxidises LDL and promotes atherogenesis. In this way it acts as a Pro-
oxidant in extracellular space. 
 
 Certainly elevations of serum GGT belong to the list of biomarker  linked 
to metabolic syndrome. It appears to be largely a reflection of secondary hepatic 
inflammation.  Although high level of GGT have been postulated to be directly 
atherogenic,59 “Syndrome x” has strong associations with progressive Non-
alcoholic fatty Liver Disease (NAFLD), age>45 years , obesity (BMI ≥ 30), 
Diabetes mellitus, AST >1 etc., which increased the  risk of developing significant          
                             ALT 
fibrosis of liver. 
 
 The frequency of nonalcoholic fatty liver disease in the general  population 
is given as 3-58%60, whereby the great variability is due to socio-economic 
differences (average value  20-23 percent).  The development of non-alcoholic 
fatty liver disease is more closely correlated with obesity than with alcohol abuse 
and simultaneously can be the cause for elevation of GGT levels in the serum. 
 
 The transaminase levels are normal (or) slightly increased.  Non alcoholic 
steetohepatitis61 is mostly associated with obesity and (or) type II diabetes. Thus 
nonalcoholic steato hepatitis is regarded as a hepatic manifestation of metabolic 
syndrome. With nonalcoholic fatty liver disease, there is a rise in GGT levels. 
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CONCLUSION : 
 
 In this study on serum GGT levels in metabolic syndrome about 56 percent 
showed elevation in Gamma-Glutamyl Transferease levels which may be due to 
Non Alcoholic Fatty Liver Disease 61 which is the hepatic manifestation of 
metabolic syndrome. 
 
 There is a very close relationship between low density lipoproteins, total 
cholesterol, triglyceride levels with serum GGT levels. Since LDL and GGT are 
independent risk factors for coronary heart disease, it will be very useful to 
describe  GGT as a potential biomarker for coronary heart disease. 
 
 The earlier the patients with dyslipidemia 62,63 are to be investigated for 
elevated GGT levels and type-II diabetes mellitus.  If the patients have elevated 
GGT levels with increased waist circumference,  lifestyle modification can 
decrease the rate of progression to diabetes and coronary heart disease.  Weight 
loss of 4kg over 3 years, 150 minutes of exercise per week, a low fatty and  high 
fibre diet can be advised. 
 
 Dietary recommendations for people with metabolic syndrome can be 
advised -  eat plenty of fruits and vegetables, avoid heavily processed foods rich in 
salt, sugar and fat. 
 
 90
 Decreased salt intake and drugs for hypertension to be taken regularly to 
control blood pressure. ACE inhibitors can be recommended, for lowering the 
blood pressure as well as to improve the insulin sensitivity and decrease the rate of 
progression to diabetes mellitus. 
 
 Metabolic syndrome is a very wide topic with lot of prospects for future 
study and research into the various aspects of risk factors, interventions, and 
treatment modalities. 
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LIST  OF  ABBREVATIONS 
 
  GGT  - Gamma Glutamyl Transferrase 
   
  W.H.O. - World Health Organization 
 
  NCEP  - National Cholesterol Education Programme. 
 
  BMI  - Body Mass Index 
 
  FBS  - Fasting Blood Sugar 
 
  HDL   - High Density Lipoprotein  
 
  TGL  - Triglycerides 
 
  TCL  - Total Cholesterol  
 
  SGOT  - Serum Glutamate Oxalo Acetate Transaminase  
 
  SGPT  - Serum Glutamate Pyruvate Transaminase 
 
  AST  - Aspartate Trans Aminase 
 
  ALT  - Alanine Transaminase 
 
  TNF  - Tumor Necrosis Factor 
 
  VD  - Vascular Disease 
 
  MS  - Metabolic Syndrome 
 
  VLDL  -  Very Low Density Lipoproteins  
 
  LDL  - Low Density Lipoproteins 
 
  POD  - Peroxidase 
 
  DHBS  - Dichloro Hydroxy Benzene Sulfonic Acid 
 
  MDH  - Malate  Dehydrogenase 
 
  PNPP  - Para Nitro Phenyl Phosphate 
 
  NAD  - Nicotinamide Adenine Dinucleotide  
 
             NAFLD           -           Non Alcoholic Fatty Liver Disease 
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